Targeting Protein Folding in N-Myc-driven Medulloblastoma

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2023 Feb 14

PMID 36786675

Authors

Gintvile Valinciute

Martine F Roussel

Affiliations

Soon will be listed here.

Abstract

Selective targeting of N-Myc-driven Sonic hedgehog (SHH) medulloblastoma has been a challenge for many years and, despite decades of research, few targeted therapy opportunities exist. Recently, Kuzuoglu-Ozturk et al. characterized the translatome of N-Myc-driven medulloblastoma as a promising therapeutic target. The study showed that N-Myc controls a subset of members of the protein folding machinery that could be inhibited pharmacologically and validated a subset of Hsp70 functions as required for medulloblastoma progression in vitro and in vivo.

References

Rickman D, Schulte J, Eilers M . The Expanding World of N-MYC-Driven Tumors. Cancer Discov. 2018; 8(2):150-163. DOI: 10.1158/2159-8290.CD-17-0273. View

Ayrault O, Godeny M, Dillon C, Zindy F, Fitzgerald P, Roussel M . Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma. Proc Natl Acad Sci U S A. 2009; 106(40):17037-42. PMC: 2761355. DOI: 10.1073/pnas.0902880106. View

Swartling F, Grimmer M, Hackett C, Northcott P, Fan Q, Goldenberg D . Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 2010; 24(10):1059-72. PMC: 2867210. DOI: 10.1101/gad.1907510. View

Hovestadt V, Ayrault O, Swartling F, Robinson G, Pfister S, Northcott P . Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nat Rev Cancer. 2019; 20(1):42-56. PMC: 9113832. DOI: 10.1038/s41568-019-0223-8. View

Cheng C, He T, Chen K, Cai Y, Gu Y, Pan L . P300 Interacted With N-Myc and Regulated Its Protein Stability via Altering Its Post-Translational Modifications in Neuroblastoma. Mol Cell Proteomics. 2023; 22(3):100504. PMC: 9984901. DOI: 10.1016/j.mcpro.2023.100504. View

Dang C . MYC on the path to cancer. Cell. 2012; 149(1):22-35. PMC: 3345192. DOI: 10.1016/j.cell.2012.03.003. View

Schwab M, Bishop J . Sustained expression of the human protooncogene MYCN rescues rat embryo cells from senescence. Proc Natl Acad Sci U S A. 1988; 85(24):9585-9. PMC: 282805. DOI: 10.1073/pnas.85.24.9585. View

Wu C, Hou S, Orr B, Kuo B, Youn Y, Ong T . mTORC1-Mediated Inhibition of 4EBP1 Is Essential for Hedgehog Signaling-Driven Translation and Medulloblastoma. Dev Cell. 2017; 43(6):673-688.e5. PMC: 5736446. DOI: 10.1016/j.devcel.2017.10.011. View

Solimini N, Luo J, Elledge S . Non-oncogene addiction and the stress phenotype of cancer cells. Cell. 2007; 130(6):986-8. DOI: 10.1016/j.cell.2007.09.007. View

10.

Jonchere B, Williams J, Zindy F, Liu J, Robinson S, Farmer D . Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo. Mol Cancer Ther. 2022; 22(1):37-51. PMC: 9808370. DOI: 10.1158/1535-7163.MCT-21-0896. View

11.

Brockmann M, Poon E, Berry T, Carstensen A, Deubzer H, Rycak L . Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell. 2013; 24(1):75-89. PMC: 4298657. DOI: 10.1016/j.ccr.2013.05.005. View

12.

Puissant A, Frumm S, Alexe G, Bassil C, Qi J, Chanthery Y . Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013; 3(3):308-23. PMC: 3672953. DOI: 10.1158/2159-8290.CD-12-0418. View

13.

Han H, Jain A, Truica M, Izquierdo-Ferrer J, Anker J, Lysy B . Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell. 2019; 36(5):483-497.e15. PMC: 6939458. DOI: 10.1016/j.ccell.2019.10.001. View

14.

Kuzuoglu-Ozturk D, Aksoy O, Schmidt C, Lea R, Larson J, Phelps R . N-myc-Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma. Cancer Res. 2022; 83(1):130-140. PMC: 9812901. DOI: 10.1158/0008-5472.CAN-22-0945. View